1433206-28-0

Basic information

• Product Name: tert-butyl 4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzylcarbamate
• Synonyms: tert-butyl 4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzylcarbamate
• CAS NO: 1433206-28-0
• Molecular Weight: 343.306
• Mol File: 1433206-28-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzylcarbamate(1433206-28-0)
• EPA Substance Registry System: tert-butyl 4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzylcarbamate(1433206-28-0)

Safety Data

• Hazardous Substances Data: 1433206-28-0(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 510771-81-0 (4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)methanamine 
• 1456610-74-4 N-Boc-4-aminomethyl-N-hydroxy-benzamidine 
• 407-25-0 trifluoroacetic anhydride 
• 66389-80-8 tert-butyl N-[(4-cyanophenyl)methyl]carbamate 
• 19227-13-5 p-toluamidoxime 
• 104-85-8 para-methylbenzonitrile 
• 51779-32-9 iminodicarboxylic acid di-tert-butyl ester 

Downstream Products

• 510771-81-0 (4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)methanamine 

Relevant articles and documents

Substituent oxadiazole compound and application thereof

The invention discloses a substituent oxadiazole compound with a novel structure. As shown in a general formula I, substituent groups in the formula are defined in the specification. The compound in the general formula I has excellent bactericidal activit

1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.